Sold as Lucentis, Susvimo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Ranibizumab (sold as Lucentis, Susvimo), first approved Jun 30, 2006, with 11 new uses approved and 0 published complete response letters.
| Lucentis | Part B | $44.8M | -65% | 21,507 |
| Susvimo | Part B | $6.1M | +172% | 493 |
| Lucentis | Part D | $1.5M | -42% | 185 |
| Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.Proliferative Diabetic Retinopathy, Diabetic Retinopathy · Southeast Retina Center, Georgia | Phase 4 | Not yet recruiting | Oct 7, 2026 |
| Changes in Intraocular Pressure After Intravitreal InjectionDiabetic Macular Edema, Neovascular Age-Related Macular Degeneration · Assiut University | — | Not yet recruiting | Sep 17, 2026 |
| Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective StudyBlepharoptosis, Age-Related Macular Degeneration · Abdulkadir Küçük | — | Recruiting | Sep 15, 2026 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)Wet Age-related Macular Degeneration · Ollin Biosciences, Inc. | Phase 3 | Not yet recruiting | Sep 11, 2026 |
| LEAP Strategy for Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration · Chinese PLA General Hospital | Not applicable | Not yet recruiting | Aug 4, 2026 |
| Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical AnesthesiaRetinopathy of Prematurity · Minia University | — | Recruiting | Jul 14, 2026 |
| Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal VasculopathyNeovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy · SANGMYUNG innovation | Phase 3 | Recruiting | Jul 10, 2026 |
| Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabDiabetic Retinopathy (DR), Diabetic Macular Edema (DME) · Osijek University Hospital | Not applicable | Recruiting | Apr 9, 2026 |
| Jun 30, 2006 | LucentisBLA 125156 · New molecular entity | Genentech | 17 | Marketed |
| Oct 22, 2021 | SusvimoBLA 761197 · New active ingredient | Genentech Inc | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA